MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

ACADIA Pharmaceuticals Inc

Cerrado

SectorSanidad

27.49 2.88

Resumen

Variación precio

24h

Actual

Mínimo

26.64

Máximo

27.67

Métricas clave

By Trading Economics

Ingresos

45M

72M

Ventas

14M

279M

P/B

Media del Sector

16.768

89.037

BPA

0.42

Margen de beneficios

25.761

Empleados

653

EBITDA

7.3M

48M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+17% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

623M

4.4B

Apertura anterior

24.61

Cierre anterior

27.49

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

ACADIA Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ene 2026, 21:55 UTC

Ganancias

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 ene 2026, 23:52 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 ene 2026, 23:40 UTC

Charlas de Mercado

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 ene 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 ene 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

22 ene 2026, 21:44 UTC

Ganancias

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 ene 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 ene 2026, 21:30 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One To Acquire Brex >COF

22 ene 2026, 21:13 UTC

Ganancias

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 ene 2026, 21:10 UTC

Ganancias

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 ene 2026, 21:06 UTC

Ganancias

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Rev $15.58B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q EPS $3.26 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Interest Margin 8.26% >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net $2.13B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Adj EPS $3.86 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Charge-Offs $3.8B >COF

22 ene 2026, 21:05 UTC

Ganancias

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

17% repunte

Estimación a 12 Meses

Media 31.31 USD  17%

Máximo 40 USD

Mínimo 21 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

8

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.845 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Neutral Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.